However, the pharmacologic or genetic inhibition of STAT3 increases IL-6 expression in GBM cells and GSCs through unclear mechanisms, suggesting that therapeutically muting STAT3-dependent IL-6 induction may inadvertently suppress the tumor immune response to GBM. The gene discussed is STAT3; the disease is neoplasm.